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I. Introduction
Obviousness, or inventive step, has been called the ultimate
bar to patentability. 2 The purpose of the nonobviousness
requirement is to complement the novelty requirement and to
extend the scope of the relevant prior art beyond anticipatory prior
art.3 This ensures that an invention constitutes a sufficient advance
in technology to warrant an exclusive right. Adoption of an
obviousness standard is a balancing act that requires weighing the
inventor's right to exclude and the public's need to gain useful
technological knowledge in exchange for that patent right. As a
consequence of its interpretive flexibility, the application of
obviousness has varied greatly among nations. This is particularly
true for its application to nucleic acid molecules.
The Agreement on Trade-Related Intellectual Property
Rights ("TRIPS") has attempted to bring some international
uniformity to the application of obviousness or inventive step
rules.4 TRIPS Article 27(1) provides that "patents shall be
1 Amy Nelson, Ph.D., is a supervisory patent examiner and interference
practice specialist with the United States Patent and Trademark Office,
in biotechnology and chemistry. She is a J.D. candidate at George
Washington University School of Law, 2005. The views expressed in this
article are her personal views and do not necessarily reflect those of
the USPTO. The author wishes to thank the Honorable Randall R. Rader
for his helpful comments and suggestions during the writing of this
article.
2 Lee Petherbridge, Intelligent TRIPS Implementation: A Strategy for Countries
on the Cusp of Development, 22 U. PA. J. INT'L EcON. L. 1029, 1053 (2001).
3id.
4 Agreement on Trade-Related Aspects of Intellectual Property Rights, April 15,
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex
IC, LEGAL INSTRUMENTS-RESULTS OF THE URUGUAY ROUND vol. 31, 33
I.L.M. 81 (1994), available at
available for any inventions, whether products or processes, in all
fields of technology, provided they are new, involve an inventive
step and are capable of industrial application. ' ,5 Exclusive patent
rights are available for all products regardless of their status as an
import or a domestic creation. 6 The TRIPS Agreement has been
ratified by 120 countries.7 TRIPS is an integral part of the WTO
Agreement, and a country cannot be a member of the World Trade
Organization ("WTO") without being a party to the TRIPS
Agreement.8 As a signatory of TRIPS, the United States agreed to
ensure that its obviousness requirement meets the standards of the
1994 Agreement.9 The European Patent Office's inventive step
requirement is also governed by the TRIPS Agreement.' 0 Japan
has both signed and ratified the TRIPS Agreement.1' Australia is
also bound by the TRIPS Agreement. 12
TRIPS, however, only sets the minimum patentability
standards with which signatories must comply.' 3 National
patentability rules may vary beyond the minimum, and member
states are free to set their own intellectual property laws. To the
extent that different countries have differing patentability
standards, those differences in national laws may be significant.
http://www.wto.org/english/tratope/tripse/tagm3_e.htm (last visited May 29,
2004) (on file with the North Carolina Journal of Law & Technology)
[hereinafter TRIPS].
5 Id. at art. 27(1).
6 See S.K. Verma, TRIPS-Development and Transfer of Technology, 27 IIC:
INT. REV. INDUS. PROP. & COPYRIGHT L. 331, 343 (1996).
7 Charles Lawson, Patenting Genetic Materials: Old Rules May Be Restricting
the Exploitation ofa New Technology, 6 J.L. & MED. 373, 384 n. 109 (1999).
8 Verma, supra note 6, at 331-32.
9 See Katsuya Saito & Rosemary Sweeney, Assessment of Inventive Step or
Obviousness in the United States, Europe, and Japan 1, at
http://www.law.washington.edu/casrip/harmonization/PDF/obviousness.pdf (last
visited May 29, 2004) (on file with the North Carolina Journal of Law &
Technology).
'
0 Id. at3.
" Eiji Katayama, The Need and Possible Means of Implementing the Convention
on Biodiversity into Patent Laws, 26 A.I.P.P.I. 44, 45 (2001).
12 Lawson, supra note 7, at 384.
13 See id. at 374-75.
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As a result, TRIPS allows for differing standards of inventive step
or obviousness under different national laws.
In recent years, there has been an explosion of patent
applications in biotechnology, particularly applications directed to
nucleic acid molecules. TRIPS countries, however, have adopted a
variety of standards for determining obviousness or inventive step
for nucleic acid molecules. Part II discusses legal standards as
applied in the United States, Australia, Europe, and Japan, with
particular emphasis on the distinctions between U.S. laws and
those of other countries. Part III discusses the implications of
having different legal standards in different countries.
II. Standards for Determining Obviousness or Inventive
Step of Nucleic Acid Molecules
A. United States
1. Statutory Law
Determination of obviousness in the United States is
governed by Section 103 of the Patent Act of 1952, which recites
that:
A patent may not be obtained though the invention
is not identically disclosed or described as set forth
in section 102 of this title, if the differences
between the subject matter sought to be patented
and the prior art are such that the subject matter as a
whole would have been obvious at the time the
invention was made to a person having ordinary
skill in the art to which such subject matter pertains.
Patentability shall not be negatived by the manner
in which the invention was made. 14
14 35 U.S.C. § 103(a) (2000).
2. Relevant Prior Art
In the United States, the prior art that is applied must be
from an analogous field, and the number of references that are
applied is not limited. 15 The prior art that can be applied includes
"secret art," i.e. pending patent applications.' 6 The prior art refers
to everything that is known, published and available to the public
in the past.1' Oral disclosures are only considered if they occurred
within the boundaries of the United States.18 The United States
provides a grace period that permits publication of the invention by
the inventor up to one year prior to filing of the patent
application. 1
9
3. Prima Facie Test
Application of Section 103 was clarified in a seminal
decision:
Under § 103, the scope and content of the prior art
and the claims at issue are to be determined;
differences between the prior art and the claims at
issue are to be ascertained; and the level of ordinary
skill in the pertinent art resolved. Against this
background, the obviousness or nonobviousness of
the subject matter is determined.2 °
One of the earliest court decisions regarding obviousness as
it applies to nucleic acid molecules in the United States related to
isolation of a human genomic DNA encoding erythropoietin
("EPO"). 21 The prior art taught an isolated monkey cDNA
encoding EPO.22 The United States Court of Appeals for the
15 Saito & Sweeney, supra note 9, at 2.
16 id"
17 Akim F. Czmus, Biotechnology Protection in Japan, the European
Community, and the United States, 8 TEMP. INT'L & COMP. L. J. 435, 439
(1994).18 See id. at 459.
19 See id.
20 Graham v. John Deere Co., 383 U.S. 1, 17 (1966).
21 Amgen Inc. v. Chugai Pharm. Co. Ltd., 927 F.2d 1200 (Fed. Cir. 1991).
22 See id. at 1208.
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Federal Circuit (hereinafter Federal Circuit) held that while it
might have been obvious to try to isolate the human genomic clone
using the monkey cDNA as a probe, it was not obvious to succeed
in isolating the human EPO gene.23 There was no reasonable
expectation of success given the high degree of degeneracy of the
24probe that was required for ultimate success. Hence, the court
focused on the likelihood that the method of DNA isolation would
succeed.
In stark contrast to the Amgen decision, more recent
decisions by the Federal Circuit have focused on the structural
obviousness of the nucleic acid molecules themselves, rather than
on the obviousness of the methods for their isolation. In In re
Bell,25 the prior art disclosed amino acid sequences for insulin-like
growth factor ("IGF") polypeptides, as well as general methods for
cloning genes.26 The court held that the claimed invention,
directed to specific nucleic acid molecules that encode human IGF,
was non-obvious because there are a vast number of nucleic acid
molecules that could encode the prior art proteins, and the prior art
failed to suggest which of the possible sequences was the human
nucleic acid molecule.27
The landmark decision In re Deue 2 8 has set the stage for
obviousness with respect to nucleic acids in recent years. The
claimed invention was directed to an isolated nucleic acid
molecule encoding heparin-binding growth factors ("HBGF"),
proteins found in urine and placental tissue that stimulate cell
division and replacement of damaged or diseased tissue. 29 The
prior art disclosed the first 19 amino acids of heparin-binding brain
mitogens ("HBBM"), proteins found in the brain that are identical
for human and bovine, and the prior art also taught general
methods of DNA isolation.30 The Federal Circuit held that
whereas structural relationships may provide the motivation to
23 Id. at 1208-09.
24 See id.
25 991 F.2d 781 (Fed. Cir. 1993).
261Id. at 783.
271 Id. at 784.
2' 51 F.3d 1552 (Fed. Cir. 1995).
29 See id. at 1554-55.
30 See id. at 1556.
obtain new compounds by modifying prior art compounds, here,
the prior art taught only proteins, not closely related DNA
molecules. 3' In view of the degeneracy of the genetic code, and
hence the multitude of DNA molecules that may encode any given
protein, knowledge of the protein does not render obvious a
particular DNA encoding it.32 Further, the Court clearly
articulated that prior art methods for isolating DNA molecules are
"irrelevant" to the obviousness test for DNA molecules thereby
obtained.33
The import of the decisions in Bell and in Deuel in the
United States is that a DNA molecule will be determined to be
obvious only if it is structurally similar to prior art products, even
if one of skill in the art would consider it obvious to obtain the
DNA molecule using familiar prior art methods. The Federal
Circuit has focused on the obviousness of the nucleic acid
sequence itself rather than on the obviousness of the method of
isolating the nucleic acid sequence.34 A DNA molecule is non-
obvious and patentable because its sequence could not have been
predicted without isolation and sequencing of the DNA molecule.35
The prior disclosure of the amino acid sequence does not render
the DNA sequence obvious due to the degeneracy of the genetic
code. 36 Prior art methods for isolating and sequencing DNA are
irrelevant. 37 As a consequence of the Federal Circuit decisions, the
United States Patent and Trademark Office ("PTO") has a
relatively low threshold for obviousness in the patenting of nucleic
acid molecules as compared to most other countries.
Interestingly, after the Bell decision the Board of Patent
Appeals and Interferences held that recombinant DNA molecules
encoding swine growth hormone were obvious.38 In Ex parte
Movva, the prior art taught the partial amino acid sequence of
"1 See id. at 1558.
32 Id. at 1558-59.
31 Id. at 1559.
34 See David Keays, Patenting DNA and Amino Acid Sequences-An Australian
Perspective, 7 HEALTH L.J. 69, 83 (1999).
31 See id.
36 See id.
31 See id.
38 Exparte Movva, 31 U.S.P.Q.2d 1027 (1993).
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swine growth hormone polypeptide, the high degree of sequence
relatedness between swine, bovine and human growth hormone
polypeptides, as well as isolated DNA molecules encoding human
and bovine growth hormone. 39 The Board held that based on the
prior art, it would have been obvious to one of ordinary skill in the
art to isolate a DNA molecule encoding swine growth hormone
using probes based on the partial amino acid sequence.40 The
Board distinguished the case from Bell because the record did not
show that a large number of nucleic acids could encode the
polypeptide as in Bell and because multiple DNA sequences
encoding growth hormone polypeptides from different species
were disclosed in the prior art unlike in Bell.41
Shortly after the Deuel decision, the Board of Patent
Appeals and Interferences held that a cDNA encoding brain beta-
amyloid polypeptide associated with Alzheimer's disease was
obvious. 2 The prior art taught a polypeptide isolated from
cerebrovascular amyloid deposits of Alzheimer's patients and
provided guidelines for synthesis of degenerate oligonucleotide
probes.43 The prior art also taught methods for constructing and
screening cDNA libraries.a The Board held that it would have
been obvious based on the prior art to isolate a cDNA encoding
brain beta-amyloid polypeptide from an adult brain cDNA
library.45 The Board reasoned that here, unlike in Bell or Deuel,
there is something in the prior art that leads to isolation of the
claimed DNA.46 Further, the Board noted that there is nothing
intrinsically wrong with considering methodology in an
obviousness analysis, depending on the logic of the rejection.47
In contrast, the Board found that there was no interference
in fact between two nucleic acid sequences with only minor
'9 See id. at 1029.
40 See id. at 1032.
41 See id. at 1033.
42 Exparte Goldgaber, 41 U.S.P.Q.2d 1172 (Bd. Pat. App. & Int. 1995).
43 Id. at 1173-74.
44 Id. at 1174.
45 Id.
461d. at 1176.
47 id.
differences. 48 Lilly disclosed a cDNA encoding human protein C,
and The University of Washington ("UW") disclosed a DNA• 49
sequence that differed at two nucleotides. The Board held that
Lilly's nucleic acid sequence, taken with the prior art, would not
have suggested the nucleic acid sequence of UW, and further that
the amino acid sequence of protein C would not have suggested to
one of skill in the art the UW nucleic acid sequence. 50 Therefore,
the Lilly nucleic acid sequence and the UW nucleic acid sequence
were patentably distinct, and there was no interference in fact.5
The Federal Circuit affirmed the Board's decision.52
Although Deuel is still the law of the land in the United
States, it appears that the Board of Appeals and Interferences may
still occasionally find fact patterns that can be distinguished from
Deuel, wherein obviousness is applicable to nucleic acid
molecules. It may be that the Federal Circuit has a more pro-
patent approach to obviousness with respect to biotechnology than
the PTO. 3 The decision in Deuel was perhaps the result of an
increasing tension between the statutory requirements of
patentability, specifically obviousness, and pressure from the
biotechnology industry that patent protection of DNA molecules is
54
necessary.
4. Secondary Criteria
In the United States, secondary considerations "might be
utilized to give light to the circumstances surrounding the origin of
the subject matter sought to be patented., 55 Secondary
considerations are an essential component of the obviousness
determination and must always be considered if offered by the
48 Bd. of Regents v. Eli Lilly & Co., 2002 Pat. App. LEXIS 176 (Bd. Pat. App.
& Int. 2002).
41 See id. at *4, *8.
5
°Id. at *12-13, *43-44.
"' Id. at *44, *48.
52 Eli Lilly & Co. v. Bd. of Regents, 334 F.3d 1264 (Fed. Cir. 2003).
53 See Phillipe Ducor, Recombinant Products and Nonobviousness: A Typology,
13 SANTA CLARA COMPUTER & HIGH TECH. L. J. 1, 42 (1997).
14 See id. at 42-43.
55 Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966).
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applicant.16 They may include failure of others, long felt but
unsolved need, unexpected results or unexpected properties,
commercial success, copying, licensing, and skepticism of skilled
artisans before the invention.57
Secondary considerations have played a role in obviousness
determinations for nucleic acid molecules. For example, in Bell
the court found that whereas the prior art taught that probes should
be greater than fourteen to sixteen nucleotides only if four to five
codons are non-degenerate, Bell used a twenty-three nucleotide
probe that was degenerate at every codon 5 8 The court clearly
considered the unexpected results of the probes employed by Bell,
the teaching away of the prior art, and the skepticism of those of
skill in the art prior to the invention in its obviousness analysis,
and deemed the invention of Bell to be non-obvious based at least
in part on these secondary considerations.59
One commentator has argued that although DNA is a
chemical compound, it is more importantly a carrier of
information. 60 The Federal Circuit, therefore, has failed to adjust
existing paradigms for obviousness to the DNA technology.6 1
Consideration of only structural similarity for DNA molecules, as
for chemical molecules, fails to recognize that DNA molecules are
informational molecules.62 This essentially eliminates the
requirement of obviousness, even when all the necessary
information is available in the prior art to identify the DNA
63molecules. Second generation DNA and protein molecules often
lack the unexpected properties that are typically required to
overcome an obviousness rejection based on secondary criteria.6 4
56 Saito & Sweeney, supra note 9, at 2-3.
57 In re Rouffet, 149 F.3d 1350, 1355 (3rd Cir. 1998).
58 In re Bell, 991 F.2d 781, 784 (2nd Cir. 1993).
59 Id. at 785.
60 Arti K. Rai, Intellectual Property Rights in Biotechnology: Addressing New
Technology, 34 WAKE FOREST L. REv. 827, 836 (1999).
61 id.
62 Ducor, supra note 53, at 44.
6 3 Id. at 45.
64 Id. at 50.
B. Australia
1. Statutory Law
Inventive step is governed by section 7(2) of the 1990
Patents Act in Australia that provides:
For the purposes of this Act, an invention is to be
taken to involve an inventive step when compared
with the prior art base unless the invention would
have been obvious to a person skilled in the relevant
art in the light of the common general knowledge as
it existed in the patent area before the priority date
of the relevant claim, whether that knowledge is
considered separately or together with either of the
kinds of information mentioned in subsection (3),
each of which must be considered separately.
65
2. Relevant Prior Art
In Australia, prior art may be any information made
available in a document or in a public act,66 hence public use or
oral disclosures may satisfy the prior art requirement. Australia,
like the United States, has geographical limitations on the prior art
that can be used, so oral disclosures may be limited to those in
Australia.67 Relevant prior art may also include, as in the United
States, information in a specification with a priority date earlier
than the claimed invention.68
Prior to 1990, the common general knowledge which was
considered for inventive step determinations was limited to
knowledge within Australia.69 However, since the 1990 Act, the
65 Patents Act, 1990, § 7(2) (Austl.).
6 6 Id. § 7(3), at 301.
67 Margo A. Bagley, Patently Unconstitutional: The Geographical Limitation
on Prior Art in a Small World, 87 MINN. L. REV. 679, 688 n.38 (2003).
68 See Patents Act, 1990, Sched. 1, at 393 (defining "prior art base").
69 See e.g., Kirin-Amgen Inc. v. Univ. of Wash. (1996) 33 I.P.R. 557, 563
(Austl.), available at http://www.austlii.edu.au/cgi-
bin/disp.pl/au/cases/cth/APO/1995/61.html (last visited Nov. 16, 2004) (on file
with the North Carolina Journal of Law & Technology).
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common general knowledge is not so restricted and need only
relate to the area of the patented invention.
70
3. Prima Facie Test
The basic rule that is applied in an obviousness analysis is
set forth in Wellcome Foundation Ltd. v. VR Lab.:
[T]he question of obviousness involves asking the
question whether the invention would have been
obvious to a non-inventive worker in the field,
equipped with the common general knowledge in
that particular field as at the priority date, without
regard to documents in existence but not prior art of
such common general knowledge.7'
The court clarifies, "[t]he test is whether the hypothetical addressee
faced with the same problem would have taken as a matter of
routine whatever steps might have led from the prior art to the
invention, whether they be the steps of the inventor or not."72 The
use of such a problem solving approach necessarily carries with it
the inherent danger of hindsight reasoning. Because one knows
the invention when performing the analysis, it is easy to find the
invention to be an obvious way to solve the problem.
To establish an inventive step with respect to nucleic acid
sequences, a similar question is generally asked, "[w]as it, for
practical purposes, obvious to a person skilled in the particular art,
armed with all the common knowledge of his or her art, that he or
she could do what the patent proposes? '73 Typically, for nucleic
acid sequences, there need only be a scintilla of invention, so the
inventive step requirement is easily satisfied in most instances.74
In fact, the inventive step requirement has not been a major
70 Patents Act, 1990, § 7(2), at 301.
71 Wellcome Found. Ltd. v. VR Lab. (Aust.) Pty. Ltd. (1984) 34 A.L.R. 213, 216
(Austl.), available at
http://www.austlii.edu.au/au/cases/cth/highct/148clr262.html (last visited Nov.
16, 2004) (on file with the North Carolina Journal of Law & Technology).72 Id. at 228.
73 Keays, supra note 34, at 79.
74 id.
obstacle to patenting DNA or amino acid sequences in Australia.
75
This may well be due to the use of hindsight resulting from the
problem solving test employed in Australia.
Although there has been no consideration by Australian
courts of the inventive step requirement for nucleic acid molecules,
the Deputy Commissioner of Patents has considered the issue in a
number of opposition proceedings.76 One of the earliest decisions
by the Australian Patent Office regarding nucleic acid molecules
was Genentech Inc. v. Celtrix Pharmaceuticals Inc.7 7 The
invention was directed to an isolated DNA molecule encoding the
insulin-like growth factor binding protein, BP53, and methods for
recombinant production of therapeutically significant quantities of
the protein.78 The Patent Office reasoned that the patent holder
provided evidence that only when hybridizations were done with
three specific pools of probes under low stringency conditions was
the BP53 DNA molecule identified, and there was no teaching or
suggestion in the prior art of using such a probing strategy
involving pools of mixed probes.79 The opposition provided no
evidence of a person working in the field using methods of
common knowledge in the art to isolate a BP53 DNA. There
were difficulties that had to be overcome in a non-routine inventive
manner to isolate the BP53 DNA molecule, and therefore there
was an inventive step.
8 1
Similarly, the Patent Office found a claimed invention
directed to a recombinant non-glycosylated human interleukin-2
patentable over the natural interleukin-2 which is a glycosylated
75 Id. at 80.
76 Dianne Nicol & Jane Nielsen, The Australian Medical Biotechnology Industry
and Access to Intellectual Property: Issues for Patent Law Development, 23
SYDNEY L. REV. 347, 365 (2001).
17 (1993) 26 I.P.R. 629 (Austl.), available at
http://www.austlii.edu.au/au/cases/cth/APO/1993/39.html (last visited May 29,
2004) (on file with the North Carolina Journal of Law & Technology).
78 Id. at 6-7.
79 Id. at 6-7.80 Id. at 6.
8 id. at 7.
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protein produced by T cells. 82 The Patent Office held that the
opposition had not shown that a particular method for purifying
non-glycosylated human recombinant interleukin-2 would have
been obvious from known techniques, and hence the opposition
had failed to demonstrate the lack of an inventive step.
More recently, there was an opposition proceeding in
Australia relating to serotonin, or 5-hydroxytryptamine ("5-HT"), a
neurotransmitter that interacts with proteins of the 5-HT receptor
family. 84 The claimed invention was directed to isolated genes
from the human 5-HT1D receptor sub-family, isolated by probing a
85human cDNA library with a dog clone, RDC4. The closest prior
art reference taught isolation of cDNA clones from dog, including
RCC4, using probes based on a family of G protein-coupled
receptors including the 5-HTIA receptor.86 The prior art reference
further proposed that the clone could be a member of the large
family of serotonin receptors but stated that functional and binding
studies will be required to confirm its function.87 The Australian
Patent Office held that without further characterization of the
RDC4 clone, the skilled worker would not have recognized its
importance and would not have used the clone to isolate the human
885-HT1D receptor gene. RDC4 was an orphan clone whose
function was unknown, and one of skill in the art would not have
probed a human library with a gene that was only partly
characterized. 89 The Patent Office found, therefore, that the
opposition had not established a lack of inventive step.
90
82 Takeda Chem. Indus. v. Hoffman-La Roche Akteingesellschaft (1996) A.P.O.
3 (Austl.), available at http://www.austlii.edu.au/au/cases/cth/APO/1996/3.html
(last visited May 29, 2004) (on file with the North Carolina Journal of Law &
Technology).
13 Id. at 7.
84 Synapic Pharm. Corp. v. Astra Aktiebolag (1998) 43 I.P.R. 461 (Austl.),
available at http://www.austlii.edu.au/cgi-
bin/disp.pl/au/cases/cth/APO/1998/49.html (last visited Nov. 12, 2004) (on file
with the North Carolina Journal of Law & Technology).
85 Id. at 462-63.
86 Id. at 472.
87 id.
88 Id. at 473.
89 Id. at 472-73.
90 Id. at 473.
In sum, the Australian Patent Office has made its inventive
step determinations based on the obviousness of methods of
isolation of the nucleic acid molecules and not based on the
structural obviousness of the nucleic acid molecules themselves, as
has been the basis for obviousness analysis in the United States.
4. Secondary Criteria
Secondary, or objective, criteria are sometimes relied upon
for obviousness determinations in Australia. For example, in
Kirin-Amgen Inc. v. University of Washington91 the claimed
invention was directed to an isolated DNA encoding
erythropoietin, as well as DNAs that hybridize to said DNA under
stringent conditions. The Australian Patent Office held that the
amino acid sequence of erythropoietin was not known in Australia
with sufficient accuracy to allow identification of the gene, and
therefore the DNA was not obvious.92 Furthermore, isolation of
the DNA was non-obvious as evidenced by the large amount of
time, money, and effort that was expended by several parties to
clone the gene without success.93 In essence, the Deputy
Commissioner of Patents found that isolating the erythropoietin
gene involved an inventive step because the cloned gene was
artificially created, and in view of secondary criteria.
This decision suggests that obviousness analysis in
Australia has become almost conflated with anticipation. Patents
on nucleic acid sequences have been granted with almost no
evidence other than the failure of the prior art to disclose the
sequence.94 This approach fails to acknowledge the widespread
recognition of the genetic dogma-that there is a gene that codes
for every protein-and that cloning the gene encoding a newly
isolated protein is the obvious next step for a person skilled in the
9' Kirin-Amgen Inc. v. Univ. of Wash. (1996) 33 I.P.R. 557 (Austl.), available
at http://www.austlii.edu.au/cgi-bin/disp.pl/au/cases/cth/APO/1995/61.html (last
visited Nov. 11, 2004) (on file with the North Carolina Journal of Law &
Technology).92 Id. at 565.
" Id. at 564.
94 Lawson, supra note 7, at 379.
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art of molecular biology. 95 Many have criticized the decisions by
the Australian Patent Office for setting too low a threshold for
obviousness, i.e. for putting too much value on the first to
sequence.96 IP Australia has routinely allowed patents on genes
with no evidence other than the sequence, thereby failing to
recognize the routine nature of cloning genes. 97 In addition, broad
claims are often granted by IP Australia to encompass genes
encoding functional derivatives or parts of the enzyme, or genes
with a percentage of similarity with the disclosed nucleic acid
sequence, or that hybridize under low stringency with the disclosed
nucleic acid sequence, or to genes that encode a modified enzyme
having multiple amino acid substitutions, deletions or alterations. 98
C. Europe
1. Statutory Law
Inventive Step is determined in Europe according to Article
56 of the European Patent Convention which states, "An invention
shall be considered as involving an inventive step if, having regard
to the state of the art, it is not obvious to a person skilled in the
art."
99
2. Relevant Prior Art
Unpublished patent applications cannot serve as prior art in
Europe.' 00 Furthermore, Europe does not have a grace period
allowing inventors to publish prior to filing for a patent.'' In
Europe, prior art includes oral disclosures from anywhere in the
95 Id.
96 Nicol & Nielsen, supra note 76, at 365.
97 Lawson, supra note 7, at 379.
98 Id. at 380-81.
99 European Patent Convention, art. 56, in VOLKER VOSSIUS ET AL., EUROPEAN
MATERIALS AND INDEX 27 (1995), available at http://www.european-patent-
office.org/legl/epc/e/contents.html (last visited May 29, 2004) (on file with the
North Carolina Journal of Law & Technology).
100 Saito & Sweeney, supra note 9, at 4.
'01 Czmus, supra note 17, at 459.
world. 10 2 The use of more than a single secondary reference is
typically considered to be beyond obviousness in Europe.'
0 3
3. Prima Facie Test
The basic approach to an obviousness determination in
Europe generally involves three steps: (1) the closest prior art is
determined; (2) the technical problem is determined by comparing
the results achieved in the invention with the closest prior art; and
(3) the obviousness of the solution is assessed in light of other art
and the knowledge of a person with ordinary skill in the art.
10 4
Even though hindsight is forbidden, determining the
technical problem solved by the invention necessarily involves
hindsight.'0 5 The basic rule in Europe is that a prima facie case of
obviousness is shown if a person of ordinary skill in the art would
(not could) have made the invention. 10 6 Unlike in the United
States, aperson of ordinary skill in the art can be a team of
experts.10
One of the earliest court decisions in Europe regarding
inventive step as it applies to nucleic acid molecules involved an
invention directed to isolated DNA molecules encoding human
tissue plasminogen activator ("t-PA"). 108 In that case, the court
held that it was obvious to the person skilled in the art to produce
human t-PA by recombinant DNA technology.10 9 Oligonucleotide
probing was a known technique, and the skilled worker would
have arrived at the claimed invention because the choice of
oligonucleotide probes did not require skill and experience of a
high order.' 0 In fact, all the teams that set out to produce human t-
PA by recombinant DNA technology succeeded.'' The court
102 Id.
103 Saito & Sweeney, supra note 9, at 4.
14id.105 id.
106 Id. at 5.
107 Id. at 4.
108 Genentech Inc. 's Patent, [1989] R.P.C. 147 (Eng. C. A. 1988).
109 Id. at 243.
'
10 Id. at 277, 282-83.
1I Id. at 244.
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reasoned that the monopoly that would be granted to the inventors
by a patent far outstrips any legitimate reward for their success in
winning the race to recombinant expression of the gene, and hence
the claimed invention failed for want of an inventive step."1 2 In the
decision, the Court focused on the obviousness of the methods of
isolating the DNA molecules, rather than on the structural
obviousness of the DNA molecules as in the United States, and the
court was greatly concerned about giving away patent rights based
on the speed of performing the methods rather than based on
ingenuity.
The Technical Board of Appeals' review of cases relating
to nucleic acid molecules, has found an inventive step when there
is evidence of particular difficulties in the isolation procedures.
For example, the Board considered claims to a DNA comprising a
coding sequence for the precursor to human IL- 1.113 Although the
prior art disclosed cloning of a murine IL-I cDNA, the prior art
also disclosed significant differences between human and murine
IL- 1. Hence, the Board held that the skilled person would not
have had a reasonable expectation that the human and murine
DNAs were so homologous that one could be used to probe for the
other, and therefore the cloning of human IL- 1 DNA was
inventive. 
1 15
The lack of availability of suitable probes was the basis for
the Board finding an inventive step for an invention directed to a
DNA molecule encoding the insulin-like growth factor binding
protein, BP53. 116 The prior art disclosed SDS-PAGE
electrophoresis of BP53 and sequencing of fifteen amino acids at
112 Id. at 247, 260.
113 Dainippon Pharm. Co. Ltd. v. Otsuka Pharm. Co. Ltd., Eur. Pat. Off., T
236/96 (1999), available at http://legal.european-patent-
office.org/dg3/biblio/t960236eul .htm (last visited May 29, 2004) (on file with
the North Carolina Journal of Law & Technology).114 Id. at 18.
115 Id. at 19.
116 Genentech, Inc. v. Celtrix Pharm., Inc., Eur. Pat. Off., T 637/97 (2000),
available at http://legal.european-patent-office.org/dg3/biblio/t970637eul .htm
(last visited May 29, 2004) (on file with the North Carolina Journal of Law &
Technology).
the amino terminus. 117 The Board held that the skilled person
would not have had a good starting point for making suitable
probes for screening DNA libraries for a BP53 DNA based on the
work on other genes because of the unique characteristics of each
gene. 118 The sequence of fifteen amino acids was useless for
designing probes due to its high level of degeneracy, and hence the
skilled person would not have had a reasonable expectation of
success in isolating a DNA molecule encoding BP53.119 The
Board concluded that the claimed invention satisfied the inventive
step requirement. 120
In contrast, the Technical Board of Appeals has failed to
find an inventive step when the methods of isolation are routine
and predictable. For example, the Board considered claims to
DNA molecules encoding preprochymosin as well as its mature
form. 121 The prior art disclosed that chymosin is a milk clotting
protein that has a precursor protein of 365 amino acids, and the
prior art also taught the isolation of a clone comprising 80% of the
prochymosin molecule. 122 The Board held that the person skilled
in the art would be reasonably confident that based on the prior art
and the standard knowledge, one could successfully clone the
DNA molecules encoding preprochymosin as well as its mature
form. Hence, the Board found that the claimed invention lacked an
inventive step.1 2
3
The Board held similarly when the claimed invention was
directed to a DNA molecule encoding human insulin-like growth
factor ("IGF") II having a particular sequence. 124 The prior art
disclosed proteins belonging to the IGF family and suggested that
the amino acid sequences of IGF-I and IGF-II could be used to
... Id. at 6-7.
18 Id. at 8-9.
"1 Id. at 9.
120Id. at 11.
121 Unilever N. V. v. Celltech Ltd. Chr. Hansens Lab. A/S, Eur. Pat. Off., T
386/94 (1996).
122 Id. at 193-94.
123 Id. at 196.
124 Chiron Corp. v. US Surgical Corp., Eur. Pat. Off., T 475/93 (1997), available
at http://legal.european-patent-office.org/dg3/biblio/t930475eul.htm (last visited
May 29, 2004) (on file with the North Carolina Journal of Law & Technology).
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determine oligonucleotides for use in screening for DNA
molecules. 125 The prior art also taught a cDNA library from
liver.126 The Board held that the skilled person would have
expected to successfully isolate an IGF-II DNA molecule by
probing the liver cDNA library, since the liver was known to be
the site of production of IGF-II, and hence the claimed subject
matter did not involve an inventive step.
127
When the prior art taught the isolation of Bacillus
thuringiensis ("Bt") genes from 32 different strains of Bt using a Bt
DNA probe, and taught that Bacillus thuringiensis Berliner
contains an insecticidal gene, the Board held that claims directed to
a DNA molecule comprising the Bt gene from Bt Berliner lacked
an inventive step because the isolation and sequencing of the Bt
Berliner gene was done by a well-established method, and there
was no evidence that any difficulties were encountered.
128
The Board similarly assessed inventive step with regard to
a claimed invention directed to a DNA molecule encoding a
mammalian monokine induced by gamma interferon ("MIG") with
at least 90% identity to particular nucleic acid sequence. 129 The
prior art disclosed an isolated mouse DNA molecule encoding
cytokine induced by interferon, which DNA molecule had 78%
identity to the particular nucleic acid sequence claimed, and the
prior art suggested studying the wide involvement of such
macrophage products because of the involvement of macrophages
in human health and disease.! 30 The Board reasoned that isolation
of the human cytokine cDNA was carried out in a straightforward
manner using the prior art DNA as a probe, and the skilled person
would have considered cloning of the human cDNA as a matter of
1251 d. at 441.
126 Id. at 443.
127 Id. at 443, 446.
128 Aventis Crop Sci. v. Agrigenetics LP Novartis AG, Eur. Pat. Off., T 1054/97
(2000), available at http://legal.european-patent-
office.org/dg3/biblio/t971054eul.htm (last visited May 29, 2004) (on file with
the North Carolina Journal of Law & Technology).
129 In re Farber, Eur. Pat. Off., T 111/00 (2002), available at
http://legal.european-patent-office.org/dg3/biblio/tOO0111 eu 1.htm (last visited
May 29, 2004) (on file with the North Carolina Journal of Law & Technology).
3 0 Id. at 2, 4.
routine experimentation since the probe was available. 13 1 Hence,
as a general rule the Board is unlikely to find an inventive step
provided that the starting materials are available and the methods
of DNA isolation are routine.
In a decision wherein the closest reference was not
technically available as prior art based on an assessment of
priority, the Board nonetheless went through an obviousness
analysis with respect to the reference.132 The claimed invention
was directed to recombinant DNA encoding the pectin lyase, pelC,
having a particular amino acid sequence. 133 Since the reference
disclosed a recombinant DNA from Aspergillus niger encoding the
pectin lyase, pelD, the Board reasoned that the problem to be
solved was isolation of a recombinant DNA encoding another
pectin lyase from A niger. 134 The Board went on to recognize that
screening for a gene encoding a protein using a homologous DNA
probe was a matter of common knowledge, and hence, it would not
have required inventive skills to isolate the pelC gene using the
pelD DNA as a probe. 135 Again, when the probe was available and
the screening methods were routine, the Board failed to find an
inventive step.
In summary, unlike the United States' approach of
evaluating the obviousness of nucleic acid molecules based on
structural similarity, Europe typically evaluates inventive step
based on the obviousness of the methods of isolation of the nucleic
acid molecules.
4. Secondary Criteria
Objective indicia of nonobviousness are generally
considered to play a very secondary role compared to the technical
131 Id. at 5-6.
132 Novartis v. DSM Gist Holding B.V., Eur. Pat. Off., T 479/97 (2001),
available at http://legal.european-patent-office.org/dg3/biblio/t970479eul.htm
(last visited May 29, 2004) (on file with the North Carolina Journal of Law &
Technology).
133 Id. at 1.
134 Id. at 11-12.
...Id. at 13.
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considerations in Europe,' 36 however, this is not to say that
secondary considerations have not played any role in
nonobviousness determinations, especially for nucleic acid
molecules. The Technical Board of Appeals at the European
Patent Office has noted that an inventive step could be found if a
claimed sequence imparts an unexpected property to the nucleic
acid molecule.' 37 The Board failed to find an inventive step when
methods of isolation were routine and the isolated gene did not
have any unexpected features. 138
On at least one occasion, the Board of was willing to find
an inventive step when the nucleic acid molecules exhibited
improved properties. In Biogen,139 the Board held that claims
directed to recombinant DNA molecules comprising specific
deposited DNA inserts encoding IFN-alpha satisfied the inventive
step requirement. 140 Although the prior art taught recombinant
expression in E. coli of a polypeptide with human leukocyte
interferon activity, and taught the means for fishing for similar
DNA molecules by hybridization, the specifically claimed DNA
inserts showed some surprising technical effects as compared to
the prior art. 141 The claimed DNA inserts were found to serve as a
precursor for IFN-alpha2, which was more than 30 times more
active than the prior art IFN-alphal.142 The structural differences,
therefore, conferred a valuable property on the DNA molecules,
and the claimed DNA molecules were found to be based on an
inventive step. 143 In sum, the secondary consideration of the
unexpected property of the DNA inserts and their encoded protein
136 Saito & Sweeney, supra note 9, at 4-5.
137 In re Farber, Eur. Pat. Off., T 111/00 (2002), available at
http://legal.european-patent-office.org/dg3/biblio/tOO01 lI eul .htm (last visited
May 29, 2004) (on file with the North Carolina Journal of Law & Technology).
138 Aventis Crop Sci. v. Agrigenetics LP Novartis AG, Eur. Pat. Off., T 1054/97
(2000), available at http://legal.european-patent-
office.org/dg3/biblio/t971054eul.htm (last visited May 29, 2004) (on file with
the North Carolina Journal of Law & Technology).
139 T 301/87, BIOGEN/Recombinant DNA, [1990] E.P.O.R. 190 (Eur. Pat. Off.
(Technical Bd. App.) 1989).
Id. at 210-211
Id. at 207, 210.142 Id. at 210.
143 Id. at 210-11.
products appeared to play an important role in the Board's
nonobviousness determination.
In a separate Biogen decision relating to the same
invention, the Board reiterated that a person skilled in the art
would not have been able to isolate the specific DNA molecules by
application of the common general knowledge. 144 Furthermore,
the Board held that because the prior art suggested using a mixed
probe, not a unique probe as used by the inventor, the prior art did
not promise success to a skilled person faced with the technical
problem set out in the patent, and therefore the claimed invention
involved an inventive step.' 45 Hence, the skepticism of skilled
artisans before the invention apparently served as a secondary
consideration in the Board's decision.
Furthermore, the Technical Board of Appeals found an
inventive step when there was evidence of others' failure to
produce the claimed invention. 146 The prior art taught bovine basic
fibroblast growth factor ("bFGF") polypeptide.147 The claims were
directed to an isolated DNA encoding a mammalian bFGF
polypeptide having a particular sequence. 148 Three companies in
addition to the applicant, however, attempted to sequence bovine
bFGF polypeptide, but all three failed to provide the correct or
complete amino acid sequence. 149 Therefore, the Board concluded
that sequencing the bovine bFGF polypeptide and isolating the
DNA that encodes it must involve an inventive step.' 50 This again
suggests that secondary considerations may play a role in
nonobviousness determinations relating to nucleic acid molecules
in Europe.
'44 T 500/91, BIOGEN/Alpha-interferon II, [1995] E.P.O.R. 69, 72 (Eur. Pat.
Off. (Technical Bd. App.) 1992).
141 Id. at 79-80.
146 T 343/98, THE SALK INSTITUTE FOR BIOLOGICAL
STUDIES/Fibroblast Growth Factor (Eur. Pat. Off. (Technical Bd. App.) 2001),
available at http://legal.european-patent-office.org/dg3/pdf/t980343eul.pdf at
13 (last visited May 29, 2004) (on file with the North Carolina Journal of Law &
Technology).
147 Id. at 8.
148 Id. at 2.
149 /d. at 9, 12.
50 Id. at 13.
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Similarly, the Board found that the lack of availability of a
suitable library, and past failure with available libraries, was
sufficient to find an inventive step.' 51 The invention was directed
to a full-length DNA encoding human protein C, and the prior art
disclosed the isolation and characterization of a partial cDNA
encoding human protein C that lacked the 5' end. 152 The Board
held that although the skilled person would have readily
undertaken to isolate a full-length DNA encoding human protein C
using the partial cDNA of the prior art, the isolation of a full-
length DNA depended on the availability of a good quality human
liver cDNA library. 153 The fact that the prior art had failed to
isolate a full length clone from their library confirmed the
importance of the quality of the library. 154 Therefore, the isolation
and characterization of the full length sequence involved an
inventive step. 1
55
So, although secondary considerations are not generally
given as much weight in an inventive step analysis in Europe as
they are in a nonobviousness analysis in the United States, they do
appear to play some role in obviousness determinations for nucleic
acid molecules.
D. Japan
1. Statutory Law
In addition to being bound by the TRIPS requirement for an
inventive step, Japan is governed by Tokkyo Ho (Japan Patent
Law) section 29(2):
Where an invention could easily have been made,
prior to the filing of the patent application, by a
person with ordinary skill in the art to which the
15' T 223/96, ELI LILLY/Protein C (Eur. Pat. Off. (Technical Bd. App.) 1999),
available at http://legal.european-patent-office.org/dg3/pdf/t960223eu 1 .pdf at
26 (last visited May 29, 2004) (on file with the North Carolina Journal of Law &
Technology).
112Id. at 1, 22-23.
113 Id. at 24-26.
114 Id. at 26.
155 Id. at 27-28.
invention pertains, on the basis of an invention or
inventions referred to in any of the paragraphs of
Subsection (1), a patent shall not be granted for
such an invention notwithstanding Subsection
(1).156
The current Japan Patent Law, including the inventive step
requirement, was formulated and took effect in 1960.157
2. Relevant Prior Art
The cited prior art must be reasonably related to the
inventor's field of technology in Japan.' 58 Also, Japan only
considers oral disclosures within its national boundaries." Japan
has a six month grace period, but it does not apply to the inventor's
own published application, so there is effectively no grace
period. 16 Secret prior art cannot be used as prior art for the
determination of inventive step in Japan.' 
61
3. Prima Facie Test
The Japanese Patent Office interprets Japan Patent Law
section 29(2) to mean that a patent should only be granted for an
improved invention showing remarkable progress over the prior art
in terms of its purpose, constitution or effect.' 62 The Japanese
Patent Office Guidelines require that in order to make a rejection
on the ground of lack of inventive step, the examiner must provide
logical reasons why a person skilled in the art could easily have
156 Japan: Japan Patent Law § 29(2) (1959), reprinted in JOHN P. SINNOTT ET
AL., 2F WORLD PATENT LAW AND PRACTICE 276 (rev. ed. 2004).
157 Sekizo Hayashi, Main Changes of Japanese Patent System and Important
Decisions: In Chronological Order from 1960, 27 A.I.P.P.I. 299, 300 (2002).
158 David Abraham, Shinpo-Sei: Japanese Inventive Step Meets U.S. Non-
Obviousness, 77 J. PAT. & TRADEMARK OFF. Soc. 528, 531 (1995).
159 Czmus, supra note 17, at 459.
160 id.
161 Saito & Sweeney, supra note 9, at 5-6.
162 John Richards, Recent Patent Law Developments in Asia, 7 FORDHAM
INTELL. PROP. MEDIA & ENT. L.J. 599, 620 (1997).
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made the claimed invention.163 The reasoning must be based on
whether there is motivation towards the claimed invention.' 64
Determination of inventive step under the Japanese system
typically consists of "1) analyzing the cited prior art; 2) comparing
the claimed invention with the cited prior art; and 3) assessing the
differences between the claimed invention and the cited prior
art.' 65 More specifically, the analysis requires one to:
(1) Identify the claimed invention and review the
teachings of the prior art;
(2) Select the most suitable prior art for comparison
with the invention;
(3) Compare the claimed invention with the selected
prior art;
(4) Recognize the common and different features
between the two without considering effects (or
"koka");
(5) Establish a logical argument as to whether or not
a person of ordinary skill in the art could have
made the claimed invention at the time of filing
on the basis of the features previously identified
in the cited prior art and the invention;
(6) Judge whether sufficient motivation exists in the
cited prior art to arrive at the claimed invention;
and
(7) If sufficient motivation exists, the application
lacks an inventive step. 1
66
For highly advanced and complex technology, "a person
with ordinary skill in the art" may be defined as "a team of experts
from various fields."' 67 As in the United States, the motivation for
the invention provided by the patent examiner may differ from that
of the applicant.168 The Japan Examination Guidelines notes four
possible types of motivation: "(1) close relation of technical fields;
163 Id. at 620-21.
'64Id. at 621.
165 Saito & Sweeney, supra note 9, at 5.
166 Abraham, supra note 158, at 529-30.
167 Saito & Sweeney, supra note 9.
168 Abraham, supra note 158, at 531.
(2) close similarity of problem to be solved; (3) close similarity of
the function and working mechanisms; or (4) suggestions in the
contents of the cited prior art."'
69
In Japan, there has been no court decision regarding
inventive step as it applies to nucleic acid molecules. There was,
however, an infringement suit based on patents to recombinant
human tissue plasminogen activator ("t-PA")."7 ° The accused
infringer produced a modified recombinant t-PA, wherein the
valine at amino acid position 245 was replaced with methionine.171
The court noted that it was possible for the average skilled person
to produce t-PA variants, that amino acid position 245 is in the
hydrophobic region not important for biological activity, and that
the mutation of valine to methionine had no effect on the function
of the protein and did not exhibit better properties. 172 The court
held that the t-PA of the accused infringer constituted an
equivalent of the patented recombinant t-PA, and therefore
infringed the patent.1
73
For nucleic acids, the Japan Patent Office has found it
difficult to apply the standard that is typically used for assessing
obviousness of chemicals, namely based on the similarity or non-
similarity of chemical structures.' 74 Because DNA is composed of
four common nucleotides, its chemical structure, and hence its
chemical properties, has no essential characteristic.' 75 In addition,
there is not a clear correlation between the chemical structure of
the DNA and the activity of the encoded protein.176 Hence, the
Japan Patent Office has found it difficult to make a presumption of
structural obviousness for nucleic acid molecules as for
169 Saito & Sweeney, supra note 9, at 6.
170 Genentech Inc. v. Sumitomo Pharm. Co. Ltd., 28 IIC: INT. REv. INDUS.
PROP. & COPYRIGHT L. 391 (1997) (English translation of Osaka High Ct.
decision).
171 1d. at 391.
172 Id. at 392-93.
173 Id. at 394.
174 Yusuke Hiraki, Patentability Requirements and Scope of Protection of
Expressed Sequence Tags (ESTs), Single Nucleotide Polymorphisms (SNPs) and
Entire Genomes, 25 A.I.P.P.I. J. 10, 13 (2000).
175 Id. at 14.
176 id.
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conventional-type chemicals.177 The assessment of obviousness,
therefore, is generally based on the ease of the process of obtaining
the nucleic acids.' 78 The Japan Patent Office applies a
presumption of obviousness based on the process, i.e. DNA
molecules are presumed to be obvious based on prior art teachings
showing standard processes for their isolation, even if no
structurally analogous compounds are disclosed in the prior art. 17 9
If evidence of the difficulties of the processes are provided, then
the DNA molecules may be determined to be non-obvious.' 80
When a gene is isolated and characterized that codes for a known
protein, even if the amino acid sequence of the protein is not
disclosed in the prior art, there may not be an inventive step.' 8 ' As
a consequence, patents to nucleic acid molecules are frequently
denied based on lack of inventive step. 82 Generally, it is the view
in Japan that if patents to nucleic acids are obtained too easily, free
research and development may be inhibited, which is contrary to
the objective of the patent system.' 83
The Japan Implementing Guidelines of 1997 ("Guidelines")
sets forth examples of the assessment of inventive step as it applies
to nucleic acid molecules.'1 84 For example, an isolated human
polynucleotide encoding a polypeptide with 80% similarity to a
known rat polypeptide and without any advantageous effect lacks
inventive step because it is common general knowledge to isolate a
human DNA encoding a particular protein using a DNA encoding
the same protein from another mammal as a probe. 185 Similarly, ahuman polynucleotide isolated from a liver cDNA library that is
177 id.
178 Id. at 13.
79 Id. at 15.
180 Id.
181 Richards, supra note 162, at 624.
182 Hiraki, supra note 174, at 16.
183 Id. at 20.
184 JAPAN PATENT OFFICE, JAPAN IMPLEMENTING GUIDELINES: EXAMPLES OF
EXAMINATIONS ON THE INVENTIONS RELATED TO GENES (DNA FRAGMENTS,
FULL-LENGTH cDNAs, AND SINGLE NUCLEOTIDE POLYMORPHISMS) (1997),
available at http://www.jpo.go.jp/tetuzuki e/t tokkyo e/dnas.htm (last visited
Nov. 16, 2004) (on file with the North Carolina Journal of Law & Technology).
185 Id. at 6, Case 6.
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part of a structural gene of unknown function lacks inventive step
because it is well-known to prepare cDNA libraries from human
organs and to randomly isolate and sequence DNAs therefrom.'
8 6
The Guidelines also set forth rules for application of
inventive step to nucleic acid sequences as follows: (1) a nucleic
acid encoding a protein has an inventive step if the protein has an
inventive step; (2) if the protein is known but its amino acid
sequence is not, the nucleic acid encoding the protein does not
have an inventive step if a person skilled in the art could easily
determine the amino acid sequence; (3) when the amino acid
sequence of the protein is known, the nucleic acid encoding the
protein does not have an inventive step; (4) when a nucleic acid is
known, a mutant of said nucleic acid which has the same properties
and functions does not have an inventive step.1 87 The Guidelines
further state that if the amino acid sequence of the protein is
known, then it would be easy to try to isolate and characterize a
nucleic acid encoding the protein by well-known, conventional
cloning techniques.' 88 The invention will be denied for lack of
inventive step based on the grounds of obviousness because
patenting of such nucleic acids would interfere with technological
development. 1 
89
4. Secondary Criteria
In Japan, "koka," or secondary considerations, especially
unexpected results or commercial success, are considered in
obviousness determinations. 190 The koka are a critical element in
establishing patentability in Japan.' 91 For example, in Genentech,
the Court held that the mutation of valine to methionine did not
186 Id. at 6-7, Case 7.
187 Yusuke Hiraki, Current Development in Biotech Patents in Japan, 22
A.I.P.P.I. J. 151, 159 (1997).
188 Id. at 159-60.
89 Id. at 160.
190 Abraham, supra note 158, at 532-33.
191 Id. at 534.
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result in a protein exhibiting better properties, and hence
constituted an equivalent of the patented recombinant t-PA.'92
The Japanese Patent Office Guidelines require that in order
to make a rejection on the ground of lack of inventive step, the
examiner must consider whether any advantageous effects occur
over the prior art. 93 A DNA molecule may be non-obvious if
evidence of the unpredictable advantages of the DNA molecule is
provided. 194 When a DNA molecule is isolated and characterized
that codes for a known protein there may be an inventive step if the
isolated DNA molecule has some advantage over other DNA
molecules encoding the known protein.195 According to the
Guidelines, an isolated human polynucleotide encoding a
polypeptide with 80% similarity to a known rat polypeptide may
have an inventive step if the DNA has an unexpected advantageous
effect.' 96 In addition, each of rules (2), (3), and (4) for application
of inventive step to nucleic acid sequences specify that if the
nucleic acid has an advantageous effect as compared to other
nucleic acids encoding the protein, then the nucleic acid has an
inventive step.' 97 An invention will not be denied for lack of
inventive step if the isolated nucleic acid has a remarkable
effect.
198
192 Genentech Inc. v. Sumitomo Pharm. Co. Ltd., 28 IIC: INT. REV. INDUS.
PROP. & COPYRIGHT L. 392-94 (1997) (English translation of Osaka High Ct.
decision).
193 Richards, supra note 162, at 620-21.
194 Hiraki, supra note 174, at 15.
195 Richards, supra note 162, at 624.
196 JAPAN PATENT OFFICE, JAPAN IMPLEMENTING GUIDELINES: EXAMPLES OF
EXAMINATIONS ON THE INVENTIONS RELATED TO GENES (DNA FRAGMENTS,
FULL-LENGTH cDNAs, AND SINGLE NUCLEOTIDE POLYMORPHISMS) 7, Case 7
(1997), available at http://www.jpo.go.jp/tetuzuki e/t-tokkyo_e/dnas.htm (last
visited Nov. 16, 2004) (on file with the North Carolina Journal of Law &
Technology).
197 Hiraki, supra note 187, at 159.
'98Id. at 160.
E. Primary Differences between United States,
Australia, Europe and Japan
Above, it has been shown that Australia, the United States,
Europe and Japan all have different means and thresholds for
assessing obviousness or inventive step. Although TRIPS provides
minimum standards for implementing countries to follow, each
individual nation is free to set stricter standards than those required
under TRIPS. Hence, the obviousness or inventive step
requirement under TRIPS Article 27(1) may be interpreted
differently under different national laws.
Prior art is interpreted under all the national laws to include
everything that is known, published and available to the public,
provided it is in an analogous field to the invention; however, only
the United States and Australia allow application of secret prior
art. The United States, Australia and Japan restrict oral disclosures
to only those that occur within their national boundaries, whereas
Europe allows oral disclosures from anywhere in the world. Only
the United States provides a one year grace period within which
the inventor may publish before filing a patent application.
Whereas the number of references that can be combined in the
United States is not limited, the use of more than two references in
Europe rarely occurs.
Japan and the United States use similar approaches in
determination of inventive step. Namely, they ask: "(1) what is
the prior art? (2) what are the differences between [the] claimed
invention and the prior art? and (3) would the invention be obvious
to a person with ordinary skill in the art?"' 199 In contrast, Europe's
approach is significantly different. Namely, they ask: "(1) what is
the closest prior art? (2) what is the objective problem solved by
the invention? and (3) was the solution reached by the invention
obvious to a person with ordinary skill in the art?' '200 Australia
similarly employs a problem-solving approach and faces the
consequent dangers of hindsight. Japan and the United States
consider all the features of the claimed invention, whereas Europe
199 Saito & Sweeney, supra note 9, at 6-7.
200 id.
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considers only those features that contribute to the solution. 20 1 A
person of ordinary skill in the art may be "a team of experts" in
Japan and Europe, but not in the United States.20 2
With respect to nucleic acid molecules, only the United
States uses a structural obviousness standard analogous to the
chemical arts. Australia, Japan, and Europe all consider the
obviousness of the method of isolation of the claimed nucleic acid
molecules. The United States applies the lowest bar for
obviousness, finding that virtually any novel nucleic acid sequence
is nonobvious. Australia, although considering the obviousness of
the method of isolation, also has a relatively low bar for
obviousness. Europe and Japan, in contrast, have a much higher
bar for obviousness, requiring evidence of significant difficulties in
the isolation procedure, or evidence of unexpected properties of the
nucleic acid molecules. As a consequence, Europe has tended to
find lack of inventive step much more frequently than the Federal
Circuit or the Board of Appeals and Interferences in the United
States. Although Australia likewise evaluates obviousness of
nucleic acids based on the obviousness of the methods of their
isolation, Europe generally recognizes a higher threshold for
inventive step than does Australia. This may, in part, be due to the
almost unavoidable hindsight analysis which occurs with the
European method of assessing inventive step, or it may be due to a
higher skill level attributed to a person of ordinary skill in the art in
Europe.
Secondary criteria, such as commercial success, failure or
skepticism of other skilled artisans, and unexpected results or
properties, generally have more weight in the United States; 20 3
however, secondary considerations have played some role in
nonobviousness analysis for nucleic acid molecules in Australia,
Europe and Japan. For example, Australia has considered the
failure of others in at least one court decision. The European
Technical Board of Appeals has considered surprising technical
effects, unexpected properties, skepticism of skilled artisans, and
failure of skilled artisans in inventive step determinations for
201 Id. at 7.
202 Id.
203 Saito & Sweeney, supra note 9, at 7.
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nucleic acid molecules. In Japan, koka have also played an
important role in inventive step analysis for nucleic acid
molecules. The Japan Patent Office has routinely considered the
unexpected, advantageous or remarkable effects of newly isolated
and characterized nucleic acid molecules before determining if
there is an inventive step.
III. The Implications of Having Different Legal Standards
Because the obviousness or inventive step requirement has
been characterized as the ultimate bar to patentability, the impact
of a low or high threshold for nucleic acid molecules is significant.
Differences in obviousness standards may be attributable to or
complementary to other differences in national patent law. For
example, it has been suggested that such differences may relate to
the presence of the first-to-file versus the first-to-invent system, to
the availability of pre-grant opposition, and to the availability of
compulsory licensing. 204 The ultimate goal of patentability
standards, and consequently obviousness standards, is to promote
research and development. Where the obviousness line is drawn,
therefore, may have a significant impact on either stimulation or
retardation of invention. The rationale for the obviousness
requirement is that most technological advances occur
incrementally. 20 5 When rapid scientific advances occur, they
generally serve first to expand and then to contract the boundaries
of patentable subject matter, as the new research tools gradually
become technologically mundane.2 °6 As methods of gene isolation
and characterization become more routine, therefore, obviousness
becomes harder to avoid.20 7
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If improper, a patent law system and its component
obviousness threshold may actually retard research and
208development. If the inventive step requirement is too easily
satisfied, patents are granted for inventions that have little or no
inventive merit. 209 A proliferation of intellectual property rights
upstream may ultimately stifle research and development
downstream. 2 1 Consequently, more upstream patent rights may
lead to fewer useful products in biotechnology.2 11 The key is to
properly distribute the incentives between basic researchers and
applied technicians in order to optimize overall research and
212development.. Raising the bar on when the patent criteria are
satisfied is one way to remove impediments to access to research
tools and techniques. 2 13 Hence, obviousness standards play a
critical role in affecting access to research materials and the extent
of secondary innovation. According to Coase's theorem, the initial
allocation of property rights does not matter because property
rights will be licensed to whomever can make the most productive
use of the property rights; however, Coase's theorem does not
apply when property rights are initially allocated improperly.214
Furthermore, whereas Coase's theorem assumes zero transaction
costs, researchers in biotechnology rely heavily on prior
research.215
Gene patents may hinder basic research and commercial
exploitation of inventions by hindering access to technology. 216
The precise impact of gene patents depends on the market niche
that the inventor occupies in the biotechnology industry.217
Whereas pioneers must be guaranteed some return for their
208 Nicol & Nielsen, supra note 76, at 374.
2 09 Id. at 365.
210 Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation?
The Anticommons in Biomedical Research, 280 SCIENCE 698, 701 (1998).
211 Id.
212 Charles R. McManis, Re-Engineering Patent Law: The Challenge of New
Technologies, 2 WASH. U. J.L. & POL'Y 1, 15 (2000).213 Nicol & Nielsen, supra note 76, at 363.
214 Rai, supra note 60, at 839.2 15 Id.
216 Nicol & Nielsen, supra note 76, at 359.
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investment, improvers may be inhibited by patents that block
access to essential research tools.2 18 As a consequence of the
relaxed standards for obviousness of nucleic acid molecules
imposed by the Federal Circuit, the risk-reward models for
investment in biotechnology research are currently different than
for traditional pharmaceutical research.21 9 It has been suggested by
some that the relaxed requirements may promote upstream
innovation, at a substantial cost to downstream innovation .2 ° New
inventors in upstream innovation require less capital investment
and achieve faster time to market. 22 It has also been argued,
however, that when the obviousness standard is low, first inventors
are not able to obtain the broad patent rights they deserve, and
patent rights are widely afforded to copied inventions.
222
Obviousness analysis of nucleic acid molecules may be
unique by virtue of the nature of the biotechnology industry.
223
Because there are many small biotechnology companies whose
only asset is intellectual property, broad cross-licensing is unlikely
to happen.224 When many inventors own small, overlapping slices
of the same pie, a breakdown in the intellectual property system
can occur. For example, where there are multiple monopolies
controlling components of a product, the price is higher than if a
single company controlled all the components, resulting in a
"patent thicket., 226 The "tragedy of the anticommons" may result
when multiple owners have a right to exclude others from a scarce
resource such that the resource becomes underutilized.227 If too
many owners hold rights to upstream research, as in a country with
218 id.
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a lower obviousness bar like the United States, it may present
obstacles to future research, especially if access to multiple
patented inventions is required to create a downstream product.228
In some areas of technology, patent pools have emerged with the
help of government, when multiple licenses are required to develop
new products.2 29 However, high transaction costs may present an
impediment to the bundling of intellectual property rights in
biotechnology. 230 Licensing costs are frequently very high in
biotechnology because it is difficult to estimate the value of an
invention. 23 Also, owners of intellectual property rights in
biotechnology are diverse and have different interests-they may
consist of federal agencies, academic institutions, or private
companies-and therefore would likely face difficulty in reaching
agreement on a licensing policy.
232
Patentability determinations, in addition to being
determinations on how to balance property rights among inventors,
are also determinations on how to balance property rights with the
233public domain. Patent applicants in Japan tend to file
applications more for defensive purposes, that is, to prevent
anyone else from getting a patent, than to enforce property
rights. 234 Historically, the intended beneficiary of a patent in Japan
has been the user of the patented invention, not the patent
holder.235 Consequently, patent seekers from the United States
236often complain that the Japanese patent system is very weak. In
the United States, in contrast, the essential purpose of a patent is to
protect the patentee, and hence claims are interpreted broadly and
237patent rights are determined based on first to invent. In Japan,the role of the patent system is to teach industry new innovations
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and encourage industrial development.238 There is a deferred
examination system, frequently delays in examination, and narrow
interpretation of claims.2 9 Industry is free to make slight
modifications or to make improvements to avoid infringement and
may even file patent applications on the slightly modified
inventions. 240 Furthermore, the practice of "patent flooding," that
is, "filing many patents to surround [patented] technology," is
common in Japan.24' Patent holders of improvements over
pioneering technology may force the patent holder of the
pioneering invention to cross-license by virtue of the compulsory
license laws in Japan.
242
With respect to nucleic acid molecules, Japan has generally
also exercised greater concern for protecting the public domain
than for protecting the property rights of inventors, whereas the
United States has applied obviousness to nucleic acid molecules in
a way that dramatically lowers the bar for patentability and
impoverishes the public domain.243 The issue of obviousness and
nucleic acid molecules has produced a split between the public and
the private domain.244 Public sector and nonprofit researchers
advocate strict application of the nonobviousness standard and
avoiding broad patent protection.245 On the other hand,
biotechnology companies argue that broad patent protection is
necessary to encourage innovation and stimulate biotechnology
research and development.246 The issue has divided public sector
and nonprofit researchers from biotechnology companies, and this
conflict transcends national boundaries.
247
The effect of TRIPS may be to shift the boundary between
the public good and private interest in favor of private interest.
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Providing for widespread patenting of biotechnology inventions
such as nucleic acid molecules may result in a reduction in the
number of producers to primarily multinational corporations.
249
This is of particular concern to those nations, like Australia, with
endemic genetic diversity. Genetic diversity is a valuable genetic
resource in Australia, with about 1 million species of animals,
plants and microbes. 250 The value of the rich genetic resources is
contained in the differences within and between genes. 25 1 Such
genetic diversity serves as a potential source of nucleic acid
molecules for inventions in the agricultural and pharmaceutical
industries. 252 The broad claims to nucleic acid molecules that are
typically issued in Australia may impose limits on subsequent
patentable subject matter and may fail to value the wide benefits of
nucleic acid molecules by restricting the full potential to exploit
253genetic diversity. The obviousness standard in Australia,
therefore, may not be generating the maximum benefit from the
grant of patent monopolies and may not be extracting the full
potential for Australians from its unique genetic resources.
2 54
The TRIPS agreement does not require other countries to
adopt the same standard of obviousness for nucleic acid molecules
as the United States, that is, a relatively generous view of
255obviousness. A country implementing TRIPS could establish a
narrow view of obviousness, raising the bar for patentability.
Fewer patents would be granted and more subject matter would
remain in the public domain.256 Alternatively, a country could
implement a standard of obviousness like the United States,
thereby lowering the bar for patentability, and allowing patents to
be granted for second or third generation innovators. 257 If
countries with significant biotechnology research and development
were to establish a higher bar for patentability for nucleic acid
249 Verna, supra note 6, at 349.
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molecules, they could create a competitive advantage over the
United States, Europe, or Japan.258 This would preserve
subpatentable information in the public domain in countries that
have been excluded by leading patent countries, allowing the
information to be used for development of next generation
products. 259 It would also encourage foreign and domestic
investment, leading to transfer of research and development from
leading patent countries to other countries, especially if labor costs
260are low and a biotechnology skill base is present.
A considerable concern with having different obviousness
standards for nucleic acids in different countries is that such may
impede sharing of information among researchers in different
countries. 261 Furthermore, imbalances between United States and
foreign patent laws create uncertainties that impede the
biotechnology industry's ability to plan for and conduct research
and development. 262 This is compounded by differences in the
extent of research and development in different countries.
Currently, over ninety percent of global patent activity occurs in
Europe, the United States, and Japan.2 63 In Australia, the majority
of patent applicants are foreign, from the United States, Japan and
Europe, whereas only about two percent of patent applications in
biotechnology originate in Australia.264 Consequently, Australian
companies and companies from other countries with less
biotechnology research are forced to seek licenses from foreign
companies from countries with substantial biotechnology
research.265
On the other hand, United States biotechnology companies
aggressively seek patent protection in Europe and other countries
in order to recoup the significant investment associated with
biotechnological research.266 The United States has alleged wide-
258 Id. at 1059.
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scale losses due to weak intellectual property protection and wide-
scale piracy of intellectual property rights in newly industrializing
countries, resulting in a loss in research and development
investments.267 Under the WTO, all member states are bound by
the Understanding on Rules and Procedures Governing the
Settlement of Disputes.268 The United States has identified
Australia as a trading partner that fails to provide adequate
intellectual property protection for United States companies.269 As
a consequence, Australia is now open to challenge under the WTO
dispute mechanisms if, for example, it employs different
patentability standards for nucleic acid molecules as compared to
other subject matter.27°
IV. Conclusion
Obviously a global patent system with a unified standard
for patentability for nucleic acid molecules would be preferable to
the current system of different national patent standards. 271 It is
possible that harmonization in examination could be reached much
more easily if the standard for obviousness was not too high
because then business factors would not have as great an impact on
the examination process.272 The patent offices could apply a low
level standard for obviousness for nucleic acid molecules in ex
parte procedures and leave the business world and courts to
consider full scale obviousness by interpartes procedures. 273 It is
also possible that an international compulsory licensing system that
harmonizes national laws could reduce the danger of the race to
patent nucleic acid molecules imperiling international scientific
collaboration. 274 In the mean time, as long as obviousness
standards for nucleic acid molecules differ among nations, the
267 Verma, supra note 6, at 333-34.
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differences, and even inequities, in distribution of property rights
between pioneering and secondary inventors, and between the
public and private domain will remain. Likewise, there will
remain a persistent barrier to international research collaboration
and a lack of free flow of information between inventors from
different countries, and inventors from different countries will
continue to be able to opportunistically exploit the differing
obviousness standards.
